Marker Therapeutics, Inc. is a clinical-stage immuno-oncology company. The Company specializes in the development and commercialization of novel T cell-based immunotherapies for the treatment of hematological malignancies and solid tumor indications. It has developed its lead product candidates from its multiTAA-specific T cell technology, which is based on the manufacture of non-engineered, tumor-specific T cells that recognize multiple tumors associated antigens (TAAs), which are tumor targets, and kill tumor cells expressing those targets. It is developing two product candidates, which include Autologous multiTAA product for the treatment of lymphoma and pancreatic cancer (MT-601) and Off-the-Shelf (OTS) product in various indications (MT-401-OTS). It has developed MT-601, a multiTAA-specific autologous T cell product capable of recognizing multiple target antigens expressed by the tumor, thereby limiting tumor adaptation by negative antigen selection or downregulation.

• Revenue in USD (TTM)5.40m
• Net income in USD-9.63m
• Incorporated2018
• Employees8.00

• Location
  Marker Therapeutics Inc2450 HOLCOMBE BLVDSUITE BCM-A, MS: BCM251HOUSTON 77021United StatesUSA
• Phone+1 (713) 400-6400
• Fax+1 (302) 655-5049
• Websitehttps://markertherapeutics.com/